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Purpose: To describe a novel mutation in the fibrillin-1 (FBN1) gene in a large Pakistani family with autosomal dominant
Marfan syndrome (MFS).
Methods: Blood samples were collected of 11 family members affected with Marfan syndrome, and DNA was isolated
by phenol-extraction. The coding exons of FBN1 were analyzed by polymerase chain reaction (PCR) and direct
sequencing. One hundred-thirty controls were screened for a mutation in the FBN1 gene that was identified in this family
by restriction fragment length polymorphism (RFLP) analysis.
Results: A novel heterozygous missense mutation c.2368T>A; p.Cys790Ser was observed in exon 19. This mutation
substitutes a highly conserved cysteine residue by serine in a calcium binding epidermal growth factor-like domain
(cbEGF) of FBN1. This mutation was present in all affected members and absent from unaffected individuals of the family
in addition to 130 healthy Pakistani controls. Interestingly all affected family members presented with ectopia lentis,
myopia and glaucoma, but lacked the cardinal cardiovascular features of MFS.
Conclusions: This is a first report of a mutation in FBN1 in MFS patients of Pakistani origin. The identification of a
FBN1 mutation in this family confirms the diagnosis of MFS patients and expands the worldwide spectrum of FBN1
mutations.
Marfan syndrome (MFS) is an autosomal dominantly
inherited syndrome with a prevalence of 1 in 5,000–10,000
individuals. The major clinical manifestations of the
syndrome include three major systems according to the Ghent
criteria i.e., the ocular, skeletal and cardiovascular systems
[1,2].
Ocular features mainly involve ectopia lentis, which is
observed in around 80% of MFS patients. Ectopia lentis is
characterized by the dislocation of the lens, which typically
occurs in patients between birth and 20 years of age after that
lens is stabilized. Other features include high myopic eyes and
retinal detachment in individuals aged 50–59 years [3,4].
According to the new Ghent criteria another cardinal feature
of MFS is aortic root aneurysm/dissection. The most common
physical features were craniofacial characteristics, high-
arched palate, positive thumb and wrist signs. If the family
history of the patient is not positive, the involvement of at least
two organ systems is required to establish the diagnosis of
MFS. Genetic screening of MFS can aid the diagnosis, as the
presence of a mutation in the fibrillin-1 gene (FBN1) in the
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presence of a major manifestation of one organ system is
sufficient to make the diagnosis [5].
There are three types of fibrillins in humans: FBN1,
FBN2 and FBN3. Fibrillins are extracellular matrix fibrillar
components which are essential for the correct function of
elastic and nonelastic tissues including blood vessels, bone
and eye [6]. Fibrillin-1 is a 350-kDa protein responsible for
head-to-tail assembly of 10–12-nm fibrillin monomers in
presence of calcium-constituting microfibrils. FBN1 forms a
large multimeric protein complex by interacting with
transforming growth factor beta (TGFβ), latent TGFb binding
protein (LTBPs), and microfibrils that interact with bone
morphogenetic protein (BMP) complexes. Depending on the
requirements of a cell or tissue the FBN1 complex can activate
extracellular matrix (ECM) sequestered growth factors or
inhibit activated growth factors. Thereby defects in fibrillin
and its associated structure e.g., due to mutation, potentially
could activate the growth factor signaling pathway, that can
lead to MFS and related disorders of the connective tissue
[7].
FBN1 is composed of three types of repeated modules.
The epidermal growth factor (EGF)-like modules contain six
highly conserved cysteine residues, which form disulphide
bonds with each other and are critical for the stabilized folding
of the domain. FBN1 has 47 such modules, and 43 of them
contain a calcium binding (cb) consensus sequence and are
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known as cbEGF-like modules [8]. The calcium ion bound in
the cbEGF-like domain performs a crucial structural role in
restricting the interdomain flexibility, which might have a role
in protein–protein interaction [9]. The second type of module
of FBN1 are transforming growth factor β1-binding (or TB)
protein-like module (TGF β1-BP-like module, or 8- Cys/TB),
which is found seven times in FBN1. This module contains
eight cysteine residues that form four disulfide bonds. The
third type of module is a hybrid module, which occurs twice
[5].
Currently more than 1,200 mutations are known in the
FBN1 gene and missense mutations account for a major
proportion (60%) of these mutations [10]. The majority of
these mutations affect one of the cbEGF domains; often
involving one of the six highly conserved cysteine residues
within the cbEGF domains. Most mutations leading to a
severe disease are found to be clustered in exons 24–32, which
encodes a central stretch of 12 cbEGF repeats. This stretch is
important in the formation of a rigid rod-like structure, which
might be involved in the formation of microfibril assembly
[11].
In this study we analyzed a five-generation family from
Pakistan. All eleven affected family members lacked the
cardinal cardiovascular features, but the diagnosis of MFS
was confirmed by the identification of a novel mutation in the
FBN1 gene.
METHODS
Patients and clinical data: In this study we recruited a five-
generation consanguineous family with two loops, one from
central Punjab and the other from the Azad Jamu and Kashmir
area of Pakistan. Eleven out of 14 affected individuals and 5
of 6 normal healthy individuals participated in the study. 130
additional normal healthy controls were recruited for the
study. After obtaining informed consent, thorough physical,
ocular and cardiovascular examinations were performed for
all participating family members.
Molecular genetic analysis: Genomic DNA was extracted
from whole blood using a conventional phenol-chloroform
method [12]. PCR amplification of the 65 coding exons and
flanking regions of the FBN1 gene was performed in the
proband (IV:13) using a PE 9700 thermocycler (Applied
Biosystems, Foster City, CA). Primers used for PCR
amplification are presented in Table 1. Briefly, for all
amplicons the following cycling conditions were applied:
initial denaturation at 94 °C for 5 min followed by 35 cycles
of 94 °C for 30 s, 64 °C for 30 s, and 72 °C for 30 s. Sequencing
reactions were performed using an ABI 3730 DNA analyzer
from Applied Biosystems. For the detection of deletions and
duplications, the SALSA MLPA kits P065 and P066 from
MRC Holland (Amsterdam, the Netherlands) were used.
Segregation of a novel missense change in exon 19 was
performed by direct sequencing of this exon in other family
members using standard conditions. The forward primer 5′-
CAG GAG TTT TGC CTT TTT GC-3′ and reverse primer 5′-
TGC CAT GTA GAA CCA CAG AA-3′ were used to amplify
a 394 base pair (bp) product containing exon 19. PCR products
were visualized on 2% agarose gel and purified by using PCR
clean-up purification plates (NucleoFast® 96 PCR;
MACHEREY-NAGEL, Düren, Germany), according to the
manufacturer’s protocol. Purified PCR products were
analyzed by Sanger sequencing in an automated DNA
sequencer (Big Dye Terminator, version 3 on a 3730 DNA
analyzer; Applied Biosystems). Sequencing results were
assembled and analyzed by using Vector NTI Advance™
2011 software from Life echnologies/Invitrogen (Bleiswijk,
The Netherlands).
Unrelated control individuals were analyzed for the novel
mutation by restriction fragment length polymorphism
(RFLP) analysis using the restriction enzyme AlwNI (New
England Biolabs, Ipswich, MA). PCR products were digested
by using 2 U of enzyme, 1× PCR buffer 4 (20 mM Tris-acetate,
50 mM potassium acetate, 10 mM Magnesium Acetate, 1mM
Dithiothreitol pH 7.9) and 16 µl of amplified PCR product,
and incubated for 2 h at 37 °C. After heat inactivation at 65 °C
the product was separated on a 3% agarose gel.
RESULTS
Clinical characteristics: Eleven affected individuals of the
family including 8 males and 3 females participated in the
study (Figure 1). All patients showed similar clinical
symptoms. In all affected members bilateral lens dislocation
occurred and lenstectomy was performed. Other ocular
symptoms included high myopia and glaucoma. None of them
displayed any cardiovascular system abnormalities on
echocardiography. Abnormalities of the skeletal system in
MFS such as tall stature, long limbs, joint hypermobility, long
narrow head, arachnodactyly, flat feet and medial
displacement of medial malleoli, hollow cheeks and recessed
or protruding jaw were noted in all individuals (Table 2).
Identification of a novel FBN1 mutation: Direct sequencing
of FBN1 revealed a novel heterozygous mutation (c.
2368T>A) in exon 19 which results in a change from a
cysteine to a serine (p.Cys790Ser; Figure 2A,B). This
missense mutation was present heterozygously in all affected
members of the family while it was absent from normal
individuals of the family as well as 130 unrelated healthy
controls.
The p.Cys790Ser mutation resides in the 12th cbEGF
domain, where it affects one of the highly conserved cysteine
residues. Cys790 is the 4th cysteine residue of this cbEGF
domain, which is predicted to form a disulphide bond with the
2nd cysteine residue (Cys776; Figure 3).
DISCUSSION
Of all mutations that have globally been identified in the
FBN1 gene, 38.6% result in a truncated FBN1 protein, and
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60.3% represent missense mutations and of which most (78%)
are localized in the cbEGF-like modules [13]. In the 43 cbEGF
domains each have six highly conserved cysteine residues
(C1-C6), which form disulphide bonds among each other (C1-
C3, C2-C4, C5-C6). We identified a novel mutation in exon
19 of the FBN1 gene in a large MFS family from Pakistan,
which, is predicted to abolish the C2-C4 (Cys776-Cys790)
disulphide bond of the 12th cbEGF domain, as the 4th cysteine
residue is replaced with serine (Cys790Ser). Missense
mutations in FBN1 that affect the cysteines, which are
essential for the correct EGF-like domain structure, act in a
dominant negative manner. Since the monomers from the
mutated allele are folded incorrectly, they assemble with the
normal monomers from the other allele creating abnormal
multimers [14,15].
So far, no clear genotype-phenotype correlations in
FBN1 have yet been established, though some correlations
have been suggested in some studies, which included a large
number of individuals (n=101, 93, 57, 81, and 76 patients).
Interestingly, a higher frequency of cysteine substitutions was
observed in MFS patients with ectopia lentis, opposed to
premature termination codon mutations [16-20]. This is in line
with the clinical findings in the family described in this study,
as all affected family members developed ectopia lentis.
Previously most of the FBN1 mutations were found in
other exons rather than exon 19. To date only four mutations
have been identified in exon 19: a frameshift mutation
observed in one Italian patient with clinical symptoms mainly
involving the skeletal and cardiovascular systems [21], and
three missense mutations in 3 sporadic patients from Belgium
with classical MFS and involvement of the cardiovascular
system [1]. All three missense mutations were present in the
8th cbEGF domain affecting the 2nd and 3rd cysteine
residues. Though all mutations identified in exon 19 have so
far been associated with involvement of the cardiovascular
system, this is not the case in the family described in this study,
as none of the affected family members showed
cardiovascular system abnormalities on echocardiography.
It has been reported that mutations in exons 24–32 are
found in MFS individuals with a more severe and complete
Figure 1. Pedigree of a Pakistani family with MFS. Squares indicates males and circles females, black symbols represents affected and white
unaffected individuals, gray symbols indicates unknown affection status. Slashed symbols represent the deceased subjects. + indicates the
normal allele, and M indicates the Cys790Ser mutation.
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phenotype, including a younger age at diagnosis and a higher
probability of developing ectopia lentis, ascending aortic
dilatation, aortic surgery, mitral valve abnormalities,
scoliosis, and shorter survival [11]. The ocular manifestations
in this family, carrying a mutation in exon 19 of FBN1, were
severe. All patients, including 4 young children, developed
ectopia lentis, myopia and glaucoma. However, no
cardiovascular system defects have been developed in the
affected individuals so far. Moreover, among skeletal
manifestations no pectus abnormalities or scoliosis have been
noted.
Loeys et al. [1] did not find distinguishing features in
patients with MFS with or without a FBN1 mutation except
for the presence of ectopia lentis, which was significantly
higher in individuals with mutations in FBN1. A significant
difference was observed between the clinical phenotype of
patients carrying a missense mutation in 11th and 12th EGF-
like domains compared with patients carrying a missense
mutation in EGF-like domains 13–18. Patients with mutations
in EGF-like domains 11 and 12 have a shorter survival, a
younger age at diagnosis, a higher probability of neonatal
presentation, and a higher risk of developing ascending aortic
dilatation than patients with a missense mutation affecting
EGF-like domains 13–17 [11]. In the Pakistani family,
carrying a mutation in the 12th EGF-like domain, patients
were also diagnosed at a young age and some of them have a
neonatal presentation, but no cardiovascular symptoms were
observed.
Marfan syndrome is characterized by a high clinical
heterogeneity. The presentation of cardinal symptoms varies
among families but also within families. The prevalence of
cardiovascular features such as mitral valve prolapse is 43%
TABLE 2. CLINICAL EVALUATION OF AFFECTED FAMILY MEMBERS.
Patient ID Manifestation III:4 III:5 III:7 IV:4 IV:5 IV:7 IV:8 IV:9 IV:11 IV:12 IV:13
Age (years)  55 40 35 30 28 12 16 8 20 6 6
Gender  M M M M M F F F M M M
Ocular
System
(i) Ectopia lentis + + + + + + + + + + +
(ii) Myopia + + + + + + + + + + +
(iii) Abnormally flat cornea - - - - - - - - - - -
(iv) Early development of
nuclear cataract
+ + + - - - + - + + +
(V) Glaucoma (IOP) R34 15 R14 R15 R14 R20 R16 R12 R18 R14 R18
  L34 15 L14 L12 L16 L24 L16 L14 R16 L12 L20
(Vi) Retinal detachment + - + + - - - - - - -
Cardiovas
cular
system
(i) Aortic root dimension
(mm)*
32 31.8 23.6 35.1 27.5 25.1 28.7 20 34 35 20
(ii) Mitral valve prolapse - - - - - - - - - - -
(iii) Dilation of pulmonary
artery
- - - - - - - - - - -
Skeletal
system
(i) Height (H; cm) 176.7 173.4 167.6 170.6 167.4 146.3 158.5 121 167.6 106.6 106.6
(ii) Arm span (AS; cm) 182 177 172 175 173 153 164 125 175 110 110
(iii) AS/H (normal <1.05) 1.03 1.02 1.02 1.02 1.03 1.04 1.03 1.03 1.04 1.03 1.03
(iv) Pectus carinatum - - - - - - - - - - -
(v) Pectus excavatum - - - - - - - - - - -
(vi) Arachnodactyly + + + + + + + + + + +
(vii) High palate with dental
crowding
+ + + + + + + + + + +
(viii) Flatfoot + + + + + + + + + + +
(ix) Characteristic face
(long narrow head,
hollow cheeks,
recessed or protruding
jaw)
+ + + + + + + + + + +
Other
manifestat
ions
(i) Hyperextensible skin - - - - - - - - - - -
(ii) Striae - - - - - - - - - - -
(iii) Hernia + + + + + - - + + - -
          IOP: intraocular pressure, R: right eye, L: left eye. *normal range 20–37 mm.
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and ascending aortic dilation is 53% in individuals in the age
group <30. It increases steadily with age to 75% and 96%,
respectively, in individuals of ≤60 years with FBN1 mutations
[22]. The affected individuals of the 5-generation family we
present here lack the cardinal cardiovascular features of MFS,
but do have the typical skeletal and ocular symptoms. The
novel mutation in the FBN1 gene identified in this family
supports the diagnosis of MFS.
Although cardiovascular features are absent in the family,
it has been reported that in some cases these features may not
manifest until adulthood. Black et al. [23] reported the
development of aortic root dilatation in the fifth decade of life
in patients presenting familial ectopia lentis at the age of 58
and 70 years. In the present family only one affected
individual has reached age 50, whereas three are in the age
group of 30–40 years, four affected individuals are in their
childhood and 3 are infants. Therefore the young age might
explain the absence of cardiovascular manifestation in these
individuals. The study of Black et al. [23] confirms the need
for life-long screening in adult patients carrying a FBN1
mutation in the absence of major manifestations.
In this family of Pakistani origin affected individuals
experience major involvement of the ocular and skeletal
systems. Interestingly, all patients in this family developed
ectopia lentis, had high myopia and glaucoma. In literature it
has been reported that glaucoma occurs in 64% of patients
with MFS and in 10% of patients with isolated ectopia lentis
[24]. Glaucoma has been observed more frequently in
spontaneous late subluxation of the lens than in the congenital
type. However, in the family described here glaucoma was
been observed in combination with early sublaxation of the
lens in all affected individuals, suggesting that predisposing
Figure 2. Sequence traces of the novel
FBN1 missense mutation Cys790Ser in
exon 19. A: A heterozygous change
T>A (indicated by arrow) is identified
in an affected family (IV:13) member.
B: The corresponding normal sequence
in an unaffected family member (IV:
10).
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factors may be present in this family, adding to the risk of
developing glaucoma.
To the best of our knowledge this is the first report of a
family with FBN1 mutations, in which all affected individuals
developed glaucoma and myopia. The presence of these
particular clinical features in all affected individuals might be
due to the novel mutation p.Cys790Ser, or alternatively may
be associated with additional genetic factors that contribute to
the disease phenotype in this family. We believe that the
p.Cys790Ser mutation affects the structure of the protein by
disturbing the arrangement of the microfilaments, and acts in
a dominant negative manner. Although more than 1,200
mutations in the FBN1 gene have been identified for MFS,
this is a first report from Pakistan, which expands the
worldwide mutation spectrum and adds to the existing
knowledge of genotype-phenotype comparisons for MFS.
Figure 3. A schematic representation of the consensus secondary
structure of a prototypical cbEGF-like domain. Calcium binding in
the NH2-terminal region of the wild-type domain is mediated by the
highly conserved amino acids highlighted in blue. The highly
conserved cysteines of the cbEGF-like domain are marked with a C,
and the lines between the cysteine residues represent disulfide
bridges. The mutation Cys790Ser affects the 4th cysteine residue,
which is predicted to form a disulfide bridge with the 2nd cysteine
residue (Cys776). The mutation abolishes the disulfide bond
formation and thus causes misfolding of the protein.
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